对于需要新生血管形成的外周微血管病变，羟苯磺酸钙能否安全使用？
Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis?
作者信息
Demirtas Sinan, Caliskan Ahmet, Guclu Orkut, Yazici Suleyman, Karahan Oguz, Yavuz Celal, Mavitas Binali
机构信息
Department of Cardiovascular Surgery, Medical School of Dicle University, Diyarbakir, Turkey.
出版信息
Med Sci Monit Basic Res. 2013 Sep 27;19:253-7. doi: 10.12659/MSMBR.889427.
BACKGROUND
Calcium dobesilate (CaD) is a member of the synthetic veno-active drug family. Only a small number of reports are available that describe the micro-angiogenic effects of CaD in the current literature.
MATERIAL AND METHODS
The antiangiogenic potential of CaD was compared with bevacizumab (Bb), which is a potent angiogenesis inhibitor, in a chick chorioallantoic membrane model. Four different concentrations (10-7, 10-6, 10-5, and 10-4 M) of drug pellet were prepared for each drug. Changes in vessel formation were scored and compared for each drug according to the previous literature.
RESULTS
The antiangiogenic behavior of CaD was lower than Bb, despite the significant dose-dependent manner of escalation. The anti-angiogenic scores of CaD were determined as 0.20, 0.47, 0.66, 1.0 in 10-7, 10-6, 10-5, and 10-4 M concentrations, respectively (average score >0.5 was significant).
CONCLUSIONS
According to the data obtained, this agent should be used carefully for cases in which angiogenesis plays an important role in healing.
背景
羟苯磺酸钙（CaD）是合成的静脉活性药物家族的一员。在当前文献中，仅有少数报告描述了CaD的微血管生成作用。
材料与方法
在鸡胚绒毛尿囊膜模型中，将CaD的抗血管生成潜力与强效血管生成抑制剂贝伐单抗（Bb）进行比较。为每种药物制备四种不同浓度（10-7、10-6、10-5和10-4 M）的药粒。根据先前文献，对每种药物的血管形成变化进行评分并比较。
结果
尽管CaD具有显著的剂量依赖性升高方式，但其抗血管生成行为低于Bb。CaD在10-7、10-6、10-5和10-4 M浓度下的抗血管生成评分分别确定为0.20、0.47、0.66、1.0（平均评分>0.5具有显著性）。
结论
根据所获得的数据，对于血管生成在愈合中起重要作用的病例，应谨慎使用该药物。
Zotero 插件